phrykt

Emmaus Life Sciences, Inc. (EMMA): who owns it and who trades it

As of Oct 30, 2026, EMMA insiders reported 4 purchases worth $15K in the last 12 months. The largest buyer was Willis C Lee (CEO), with $15K.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, EMMA insiders reported $15K of open-market purchases and $0 of sales.

Purchases, 12 months
$15K
4 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Aug 31, 2026
Filed Sep 2, 2026

Purchases and sales by month

$15K$15KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 31, 2026Willis C LeeCEOPurchase100,000$0.05$5KForm 4
Aug 28, 2026Willis C LeeCEOPurchase94,767$0.06$5.7KForm 4
Aug 27, 2026Willis C LeeCEOPurchase50,000$0.05$2.5KForm 4
Aug 25, 2026Willis C LeeCEOPurchase46,000$0.04$1.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Willis C LeeCEO, Director$15K–Aug 31, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

EMMA short interest

Low short interest. Less than 0.1% of EMMA shares are sold short. Over the last 12 reports the number of shares short went up 506%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9,890 EMMA shares were sold short, 0.0% of the shares outstanding, up 229.2% from the report before. At the average daily volume of 25,967 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.01%May 15Oct 300.03%

Days to cover

1.0May 15Oct 301.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269,8900.01%+229%25,9671.0
Oct 15, 20263,0040.00%-78%19,9591.0
Sep 30, 202613,9190.02%-14%104,5211.0
Sep 15, 202616,1770.02%-25%81,0121.0
Aug 31, 202621,5390.03%+610%885,6051.0
Aug 14, 20263,0330.00%No change115,5751.0
Jul 31, 20263,0330.00%No change26,3481.0
Jul 15, 20263,0330.00%+86%65,5151.0
Jun 30, 20261,6330.00%No change110,9991.0
Jun 15, 20261,6330.00%No change139,7601.0
May 29, 20261,6330.00%No change83,4191.0
May 15, 20261,6330.00%No change138,1991.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Emmaus Life Sciences company events

Emmaus Life Sciences filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Aug 14, 2026.

  1. Aug 14, 2026ResultsReleased financial results. Filing
  2. May 15, 2026ResultsReleased financial results. Filing
  3. Apr 17, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers Appointment of Director By written consent on April 16, 2026, the directors of Emmaus Life Sciences, Inc. appointed Henry H. Du to fill the vacancy on the… Filing
  4. Apr 14, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers Resignation of Director On April 13, 2026, Jon Kuwahara resigned as a director of Emmaus Life Sciences, Inc., effective April 15, 2026. Filing
  5. Mar 31, 2026ResultsReleased financial results. Filing
  6. Mar 4, 2026AgreementReference is made to the description of the License and Exclusive Distribution Agreement, or License Agreement, dated as of December 24, 2025 between Emmaus Life Sciences, Inc. and NeoImmuneTech, Inc. (KOSDAQ: 950220.KQ), or NIT, reported in our Current Report on Form 8-K filed with the Securities… Filing
  7. Dec 31, 2025AgreementEmmaus Life Sciences, Inc. and NeoImmuneTech, Inc. (KOSDAQ: 950220.KQ), or NIT, entered into a License and Exclusive Distribution Agreement, or License Agreement, dated as of the same day pursuant to which we granted NIT an exclusive (including as to Emmaus) license to all our rights to market… Filing
  8. Dec 22, 2025AgreementEmmaus Life Sciences, Inc. entered into an Exchange Agreement dated as of the same day pursuant to which we agreed to issue to a single individual 6,332,692 shares of common stock of the company valued for this purpose at approximately $0.38 per share and a convertible promissory note in the… Filing
  9. Dec 19, 2025LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers Resignation of Director On December 15, 2025, Ian Zwicker resigned as a director of Emmaus Life Sciences, Inc., effective December 31, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Emmaus Life Sciences financials

Questions about Emmaus Life Sciences, Inc. (EMMA) stock

Are EMMA insiders buying or selling?

In the last 12 months, EMMA insiders reported 4 open-market purchases worth $15K and no sales. The latest trade was on Aug 31, 2026. See every trade.

What is the short interest in EMMA?

As of Oct 30, 2026, 9,890 EMMA shares were sold short, 0.0% of the shares outstanding, up 229.2% from the report before. At the average daily volume of 25,967 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.